Background The need for economical rabies post-exposure prophylaxis (PEP) is increasing in developing countries. Implementation of the two currently approved economical intradermal (ID) vaccine regimens is restricted due to confusion over different vaccines, regimens and dosages, lack of confidence in intradermal technique, and pharmaceutical regulations. We therefore compared a simplified 4-site economical PEP regimen with standard methods. Methods Two hundred and fifty-four volunteers were randomly allocated to a single blind controlled trial. Each received purified vero cell rabies vaccine by one of four PEP regimens: the currently accepted 2-site ID; the 8-site regimen using 0.05 ml per ID site; a new 4-site ID regimen (on day 0, approximately 0.1 ml at 4 ID sites, using the whole 0.5 ml ampoule of vaccine; on day 7, 0.1 ml ID at 2 sites and at one site on days 28 and 90); or the standard 5-dose intramuscular regimen. All ID regimens required the same total amount of vaccine, 60% less than the intramuscular method. Neutralising antibody responses were measured five times over a year in 229 people, for whom complete data were available. Findings All ID regimens showed similar immunogenicity. The intramuscular regimen gave the lowest geometric mean antibody titres. Using the rapid fluorescent focus inhibition test, some sera had unexpectedly high antibody levels that were not attributable to previous vaccination. The results were confirmed using the fluorescent antibody virus neutralisation method. Conclusions This 4-site PEP regimen proved as immunogenic as current regimens, and has the advantages of requiring fewer clinic visits, being more practicable, and having a wider margin of safety, especially in inexperienced hands, than the 2-site regimen. It is more convenient than the 8-site method, and can be used economically with vaccines formulated in 1.0 or 0.5 ml ampoules. The 4-site regimen now meets all requirements of immunogenicity for PEP and can be introduced without further studies. Trial Registration Controlled-Trials.com ISRCTN 30087513
References
[1]
Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, et al. (2005) Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83: 360–8. doi: /S0042-96862005000500012
[2]
Meslin F-X (2007) Rabies in Asia: Current scene and WHO's role in control. Conference Proceedings of RIACON-2007 First Conference of Rabies in Asia (RIA) Foundation. Bangalore, India. 3–4th March: 2.
[3]
Mallewa M, Fooks AR, Banda D, Chikungwa P, Mankhambo L, et al. (2007) Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg Infect Dis 13: 136–9. doi: 10.3201/eid1301.060810
[4]
Dodet B (2006) Preventing the incurable: Asian rabies experts advocate rabies control. Vaccine 24: 3045–9. doi: 10.1016/j.vaccine.2005.10.015
[5]
World Health Organization Expert Consultation on rabies. WHO Technical Report Series 931 First Report. WHO, (2006) Available: http://www.wpro.who.int/NR/rdonlyres/B1E？D8443-0993-408C-BF09-D1D06A6E1B45/0/FINA？LTEXTWHOTechnicalReportSeries090605.pdf Accessed 25 February 2008.
[6]
Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, et al. (1985) Economical multiple-site intradermal immunisation with human diploid- cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet i: 1059–62. doi: 10.1016/S0140-6736(85)92367-0
[7]
Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein DB (1990) Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 335: 896–8. doi: 10.1016/0140-6736(90)90488-Q
[8]
Strady C, Jaussaud R, Beguinot I, Lienard M, Strady A (2000) Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. Vaccine 18: 2661–7. doi: 10.1016/S0264-410X(00)00054-2
[9]
Jaijaroensup W, Tantawichien T, Khawplod P, Tepsumethanon S, Wilde H (1999) Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin Infect Dis 28: 913–4. doi: 10.1086/517241
[10]
Deshpande A, Briggs DJ, Branzhoff A (2000) Investigation of immune responses to purified chick embryo cell tissue culture rabies vaccine (PCECV) in HIV infrected individuals using a simulated post-exposure regimen. Proceedings of XIII International AIDS conference. Durban, South Africa. July 9–14. pp. 163–8.
[11]
Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V (2001) Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis 33: E122–4. doi: 10.1086/324087
[12]
Thisyakorn U, Pancharoen C, Ruxrungtham K, Ubolyam S, Khawplod P, et al. (2000) Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis 30: 218. doi: 10.1086/313610
[13]
Goswami A, Plun-Favreau J, Nicoloyannis N, Sampath G, Siddiqui MN, et al. (2005) The real cost of rabies post-exposure treatments. Vaccine 23: 2970–6. doi: 10.1016/j.vaccine.2004.12.008
[14]
Warrell MJ (2003) The challenge to provide affordable rabies post-exposure treatment. Vaccine 21: 706–9. doi: 10.1016/S0264-410X(02)00585-6
[15]
World Health Organization (1997) WHO Recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO/EMC/ZOO.96.6. WHO, 1997. Available: http://whqlibdoc.who.int/hq/1996/WHO_EMC？_ZOO_96.6.pdf Accessed 25 February 2008.
[16]
Ambrozaitis A, Laiskonis A, Balciuniene L, Banzhoff A, Malerczyk C (2006) Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. Vaccine 24: 4116–21. doi: 10.1016/j.vaccine.2006.02.036
[17]
Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, et al. (1986) Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 314: 280–4. doi: 10.1056/NEJM198601303140504
[18]
Bourhy H, Sureau P (1990) Laboratory methods for rabies diagnosis. Paris: Institut Pasteur. pp. 191–3.
[19]
Feyssaguet M, Dacheux L, Audry L, Compoint A, Morize JL, et al. (2007) Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people. Vaccine 25: 2244–51. doi: 10.1016/j.vaccine.2006.12.012
[20]
Cliquet F, Aubert M, Sagne L (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 212: 79–87. doi: 10.1016/S0022-1759(97)00212-3
[21]
OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 5th Edition (2004) Chapter 2.2.5. Rabies. OIE, Available: http://www.oie.int/Eng/Normes/Mmanual/A_？00044.htm Accessed 25 February 2008.
[22]
Newcombe RG (1998) Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17: 873–90. doi: 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
[23]
Bland JM, Altman DG (1995) Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 346: 1085–7. doi: 10.1016/S0140-6736(95)91748-9
[24]
Khawplod P, Tantawichien T, Wilde H, Limusanno S, Saikasem A, et al. (2002) Use of rabies vaccines after reconstitution and storage. Clin Infect Dis 34: 404–6. doi: 10.1086/324507
[25]
Khawplod P, Wilde H, Sirikwin S, Benjawongkulchai M, Limusanno S, et al. (2006) Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 24: 3084–6. doi: 10.1016/j.vaccine.2006.01.051
[26]
World Health Organization (2007) Rabies vaccines. WHO position paper. Wkly Epidemiol Rec. 82. : 425–435. Available: http://www.who.int/wer/2007/wer8249_50.p？df Accessed 25 February 2008.
Meslin FX (2005) Rabies as a traveler's risk, especially in high-endemicity areas. J Travel Med 12: Suppl 1S30–40. doi: 10.2310/7060.2005.12055
[29]
Khawplod P, Wilde H, Tepsumethanon S, Limusanno S, Tantawichien T, et al. (2002) Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin. Clin Infect Dis 35: 1562–5. doi: 10.1086/344954
[30]
Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, et al. (2000) Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 78: 693–8.
[31]
Moore SM, Ricke TA, Davis RD, Briggs DJ (2005) The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. Biologicals 33: 269–76. doi: 10.1016/j.biologicals.2005.06.005
[32]
Suntharasamai P, Chanthavanich P, Supanaranond W, Warrell MJ (1988) One year booster vaccination with purified vero cell rabies vaccine. Trans R Soc Trop Med Hyg 82: 633. doi: 10.1016/0035-9203(88)90539-1
